Ask AI
ProCE Banner Activity

Case Series Evaluating Long-acting Lenacapavir in People With HIV and High Baseline Resistance

Conference Coverage
Slideset

In this retrospective case series of highly treatment-experienced people living with HIV and high rates of documented NNRTI or INSTI resistance, initiation of lenacapavir-based treatment resulted in high rates of virologic suppression, including in individuals with detectable HIV-1 RNA at baseline.

Released: February 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions